Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Osteoarthritis Pipeline Market H1 2016 Global Review Report


News provided by

ReportsnReports

28 Apr, 2016, 06:00 GMT

Share this article

Share toX

Share this article

Share toX

PUNE, India, April 28, 2016 /PRNewswire/ --

New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this H1 2016 Osteoarthritis Pipeline report include A. Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., Addex Therapeutics Ltd, Akari Therapeutics, Plc, Amura Holdings Limited, Arcarios BV, Asahi Kasei Pharma Corp., Asklepios BioPharmaceutical, Inc., Astellas Pharma Inc., Asterias Biotherapeutics, Inc., Axsome Therapeutics, Inc., Biopharm GmbH, Can-Fite BioPharma Ltd., Cara Therapeutics, Inc., Cardax Pharmaceuticals, Inc., Cellceutix Corporation, Cellular Biomedicine Group, Inc., Chong Kun Dang Pharmaceutical Corp., Dong-A ST Co., Ltd., Eli Lilly and Company, Evgen Pharma PLC, Galapagos NV, Genequine Biotherapeutics GmbH, GlaxoSmithKline Plc, IntelliCell BioSciences Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., K-Stemcell Co., Ltd., Levolta Pharmaceuticals, Inc., Medivir AB, Merck KGaA, Mesoblast Limited, Mor Research Application Ltd, NicOx S.A., Nordic Bioscience A/S, Novartis AG, Ocata Therapeutics, Inc., Omeros Corporation, Ono Pharmaceutical Co., Ltd., OrthoCyte Corporation, Osteologix Holdings Plc, Pfizer Inc., Pharmalink AB, PLx Pharma Inc., ProteoThera, Inc., Regeneus Ltd, ReqMed Company, Ltd., Sanofi, Seikagaku Corporation, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., STELIS Biopharma Pvt. Ltd., Stempeutics Research Private Limited, Symic Biomedical, Inc., Takeda Pharmaceutical Company Limited, TissueGene, Inc., Upsher-Smith Laboratories, Inc., Yooyoung Pharmaceutical Co., Ltd., Yuhan Corporation, Yungjin Pharm. Co., Ltd., Zimmer Biomet Holdings, Inc. and Zynerba Pharmaceuticals, Inc.

Complete report on H1 2016 pipeline review of Osteoarthritis with 102 market data tables and 17 figures, spread across 108 pages is available at http://www.reportsnreports.com/reports/531489-osteoarthritis-pipeline-review-h1-2016.html .

Drugs Profiles discussed in this report include (apocynin + paeonol), (clodronate disodium + hyaluronic acid), ABT-981, AlloJoin, AM-3701, AM-3876, Anatabine, Antibody for Osteoarthritis, Antibody to Inhibit TGF-Beta 1 for Osteoarthritis, ARC, AS-001, ASP-7962, BNP-OA, BRM-421, CDX-085, celecoxib, CHND-1, CKD-941, clodronate disodium, CR-8357, CR-845, CRB-0017, CS-30MS02, DA-5202, DIS-BIO-EPS, DNX-314, Drug for Bone Diseases and Osteoarthritis, Drug for Osteoarthritis, Drugs to Inhibit Renin Angiotensin for Osteoarthritis, Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture, Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders, duloxetine hydrochloride DR, fasitibant chloride, GLPG-1972, GQ-203, GQ-303, GSK-2394002, GZ-389988, JD-4000 Series, Kartogenin, KBP-056, ketoprofen, KM-278, LEVI-04, LH-023, LNA-043, MIV-711, Monoclonal Antibodies for Inflammation and Osteoarthritis, Monoclonal Antibody for Osteoarthritis, MOR-106, MSBCAR-001, naproxcinod, NBS-101, NStride APS, OAX-1, ONO-4474, OTXCP-03, OTXCP-07, pentosan polysulfate sodium, Peptide for Osteoarthritis, piclidenoson, PL-1100, PRO-1, Progenza, Protein for Osteoarthritis, Protein for Osteoarthritis and Asthma, Protein for Rheumatoid Arthritis and Osteoarthritis, Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome, PRX-167700, Recombinant Peptides for Osteoarthritis, Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS, Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis, Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis, ReJoin, Salmon Calcitonin, SAR-396049, SB-061, SBL-005, SI-613, SM-04690, Small Molecule for Degenerative Arthritis, Small Molecule for Osteoarthritis, Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders, Small Molecule to Inhibit MMP13 for Osteoarthritis, Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis, Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders, Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders, Small Molecules for Osteoarthritis, Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders, Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis, Small Molecules to Inhibit Complement System Protein for Osteoarthritis, Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis, Small Molecules to Inhibit MMP-13 for Osteoarthritis, sprifermin, Stem Cell Therapy for Autoimmune Diseases, Stem Cell therapy for CNS, CVS, Dermatological, Immnuological and Metabolic Disorders, Stem Cell Therapy for Degenerative Arthritis, Stem Cell Therapy for Knee Osteoarthritis, Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy, Stem Cell Therapy for Osteoarthritis, Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases, Stempeucel, Stromal Cell Therapy for Arthritis, Sulforadex, tonogenchoncel-L, TPX-100, TRBN-0224, UGP-302, VOLT-01, X-0002, XT-101, XT-150, YH-14619, YRA-1909, YY-1201, zoledronic acid and ZYN-002.

Order a copy of H1 2016 Osteoarthritis pipeline market research report @ http://www.reportsnreports.com/Purchase.aspx?name=531489 .

This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.